These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12663718)

  • 1. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
    Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
    Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
    Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
    Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
    Adjei AA; Mauer A; Bruzek L; Marks RS; Hillman S; Geyer S; Hanson LJ; Wright JJ; Erlichman C; Kaufmann SH; Vokes EE
    J Clin Oncol; 2003 May; 21(9):1760-6. PubMed ID: 12721252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
    Macdonald JS; McCoy S; Whitehead RP; Iqbal S; Wade JL; Giguere JK; Abbruzzese JL
    Invest New Drugs; 2005 Oct; 23(5):485-7. PubMed ID: 16133800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
    Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
    Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
    Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
    Izbicka E; Campos D; Carrizales G; Patnaik A
    Anticancer Res; 2005; 25(5):3215-23. PubMed ID: 16101130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
    Venkatasubbarao K; Choudary A; Freeman JW
    Cancer Res; 2005 Apr; 65(7):2861-71. PubMed ID: 15805288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
    Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
    Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
    Rao S; Cunningham D; de Gramont A; Scheithauer W; Smakal M; Humblet Y; Kourteva G; Iveson T; Andre T; Dostalova J; Illes A; Belly R; Perez-Ruixo JJ; Park YC; Palmer PA
    J Clin Oncol; 2004 Oct; 22(19):3950-7. PubMed ID: 15459217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
    Heymach JV; Johnson DH; Khuri FR; Safran H; Schlabach LL; Yunus F; DeVore RF; De Porre PM; Richards HM; Jia X; Zhang S; Johnson BE
    Ann Oncol; 2004 Aug; 15(8):1187-93. PubMed ID: 15277257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
    Karp JE
    Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.